vimarsana.com
Home
Live Updates
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients : vimarsana.com
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients
—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments—
TEL AVIV, Israel, Jan. 3, 2023... | January 3, 2023
Related Keywords
New York ,
United States ,
Jerusalem ,
Israel General ,
Israel ,
Dale Pfost ,
Irina Koffler ,
Barbara Lindheim ,
Sheila Sherlock ,
Massimo Pinzani ,
Rifaat Safadi ,
Digestive Health ,
University College London ,
Division Of Liver Diseases ,
Lifesci Advisors ,
Mount Sinai School Of Medicine ,
Institute For Liver ,
Chemomab Therapeutics Ltd ,
Nasdaq ,
Hadassah University Hospital ,
Strategic Communications ,
Prnewswire Chemomab Therapeutics Ltd ,
Primary Endpoint ,
Physiologic Assessments ,
Chief Executive Officer ,
Sheila Sherlock Chair ,
Visiting Scholar ,
Liver Diseases ,
Mount Sinai School ,
New York City ,
Principal Investigator ,
Private Securities Litigation Reform ,
Liver Fibrosis Biomarker ,
Sci Advisors ,
Public Relations ,
Chemomab Therapeutics Ltd Stock Exchange ,
News ,
Information ,
Press Release ,
Pet ,
Primary ,
Ndpoint ,
F ,
Safety ,
End ,
Tolerability ,
Howed ,
Positive ,
Activity ,
Cross ,
Multiple ,
Liver ,
Ibrosis ,
Biomarkers ,
Hysiologic Cmmb Us16385c1045 ,
vimarsana.com © 2020. All Rights Reserved.